WO2009070916A1 - A pharmaceutical composition for treating depression and a preparation process thereof - Google Patents

Abstract

A pharmaceutical composition for treating depression comprising Fructus Jujubae and glycyrrhiza uralensis as raw materials, and a preparation thereof are disclosed.

Description

 Medicine composition for treating depression and preparation method thereof

Technical field

 The present invention relates to a group of pharmaceutical compositions comprising licorice and jujube which are used as raw materials for the treatment of depression, which can be used as medicines, nutrients and health foods. The present invention also relates to a method of preparing the above pharmaceutical composition for treating depression.

Background technique

 Depression is a common disease. According to statistics, about 25% of women in the general population have experienced depression during their lifetime, and about 10% of men have experienced depression (Zhang Chunxing: Modern Psychology) . Data from the World Health Organization (WHO): The incidence of depression in the world is about 11%. There are currently about 340 million people with depression in the world, and this number is still on the rise. The survey found that in the next 20 years, depression It will rise to the second most common disease in the world.

 In the prior art, the antidepressant drugs are mainly based on Prozac, Serote, Zoloft, etc. (SS-, SNRI, NDRI, etc. 5-HT, NE, DA reuptake inhibitors), and the mechanism of action is Increase the content of serotonin and other components in the human nervous medium to alleviate the symptoms of depression.

However, the anti-depressant drugs that have been asked have different degrees of side effects, such as: increased suicide rate, headache, dizziness, dizziness, insomnia, lethargy, tinnitus, dry mouth, anorexia, increased appetite, weight gain, blood pressure, gastrointestinal Discomfort, nausea, nausea, vomiting, indigestion, diarrhea, constipation, lower limb pain, skin rash, trembling, cramps, sweating, edema, loss of libido, sexual incompetence, etc. In recent years, anti-depressant drugs such as Prozac have become a serious concern in the society. The US Food and Drug Administration (FDA) in 2004 requested pharmaceutical companies to relabel the main 32 anti-depressants on the market. Part of its side effects and warnings, and stressing to medical staff that these drugs may increase the chances of suicide in children and adolescents. Among them, the Cellot-Garonne province was found to have potential safety hazards as early as 1996, and has been recalled from the market since 2001. In June 2004, the US Attorney General of New York accused the British GlaxoSmithKline of deceptively concealing the use of Selot and the risk of increasing the risk of suicidal tendencies and behavior among adolescents in order to make a profit. In this context, how to develop a new generation of drugs with low side effects and significant anti-depression effects has become A concern for the global pharmaceutical community.

 In recent years, scientists in the international medical community have made new breakthroughs in the study of the pathogenesis of depression. It has been found that in addition to the treatment of depression by 5-HT, NE, and DA reuptake inhibition, it is possible to adopt regulation. The post-posterior mechanism of action is used to treat depression, and it has become a research and development hotspot for antidepressants in the pharmaceutical industry due to the advent of the drug-restricting mechanism Rolipram. Rollipura is an inhibitor of phosphodiesterase 4 (PDE4). Clinical trials have shown that it has significant antidepressant effects, but it is forced to terminate R&D due to strong vomiting. Pula has developed a new generation of "receptor-poster mechanism anti-depression drugs" research and development ideas.

 Therefore, in view of the shortcomings in the prior art, the applicant has carefully studied and explored, and in the spirit of perseverance, finally conceived the pharmaceutical composition of the present invention for treating depression with licorice and jujube as raw materials. The method is as follows, which is a brief description of the invention.

Summary of the invention

 In order to overcome the deficiencies of the existing pharmaceutical preparations, the inventors have studied the pathogenesis and mechanism of action of traditional Chinese medicine for treating depression in combination with modern medical and pharmacological theories. On the basis of this, the inventors have proposed the present invention, and the object thereof is to provide A pharmaceutical composition or health food for treating depression caused by licorice and jujube as raw materials. The pharmaceutical composition is characterized by a clear functional component and a mechanism of action, and the main functional component can be quantified, so that the quality is stable, the curative effect is obvious, the safety is high, and the administration is convenient.

 Another object of the present invention is to provide a pharmaceutical composition for preparing a depression or a health food prepared by using the above-mentioned licorice or jujube as a raw material.

The solution of the medicament of the invention is the result of intensive research and exploration by the inventors, according to the pathology and pharmacology theory of modern medical treatment of depression, especially the anti-depression drug target research combined with the post-receptor mechanism, after a large number of animal experiments prove: Glycyrrhizic acid (glycyrrhetinic acid) is a strong inhibitor of cAMP phosphodiesterase (CAPD); jujube cAMP can increase the expression of cAMP in human body, extracting jujube cAMP with very small content (about one ten thousandth) in jujube The results of experiments with the jujube extract containing 1% jujube cAMP for anti-test depression have shown that it has obvious anti-test inhibition. The function of stagnation, while the jujube extract containing normal jujube cAMP does not have obvious anti-experimental depression function; the combination of glycyrrhizic acid (glycyrrhetinic acid) and jujube cAMP, synergistic effect, can further improve the utilization of cAMP Degree and activity, while the concentration and activity of cAMP are enhanced, it can increase the synthesis and release of neurotransmitters such as norepinephrine (NE), thus achieving significant anti-depression function. Since the conversion rate of glycyrrhizic acid to glycyrrhetinic acid in the human body is almost 100%, glycyrrhetinic acid, which is more fat-soluble than glycyrrhizic acid, can enter the brain through the blood-brain barrier, so glycyrrhizic acid inhibits CAPD and has anti-depression effect. It is carried out by in vivo conversion to glycyrrhetinic acid, and therefore, the pharmaceutical composition of the present invention can be processed by using glycyrrhizic acid or glycyrrhetinic acid as a raw material.

 Licorice and jujube are the commonly used medicinal materials and foods for traditional Chinese medicine and food supplement diets for thousands of years. In the course of food and clinical use for thousands of years, the safety of licorice and jujube have been fully proved, while taking licorice and large Jujube does not cause side effects such as strong vomiting, so the inventor proposed to use licorice and jujube as raw materials to make oral or health foods for the treatment of depression, especially the clear functional ingredients, long-term safety is high, will not cause New technical solutions for side effects such as strong vomiting to improve the deficits produced in the prior art.

 The present invention discloses a pharmaceutical composition for treating depression, which is prepared by using licorice and jujube as raw materials.

 Preferably, the pharmaceutical composition of the present invention is prepared by including 2 to 32 parts by weight of licorice and 2 to 42 parts by weight of jujube.

 Preferably, the pharmaceutical composition of the present invention is prepared by including 5 to 15 parts by weight of licorice and 4 to 20 parts by weight of jujube.

 According to another concept of the present invention, the present invention is a pharmaceutical composition for treating depression, which is prepared by using licorice and jujube extract as raw materials.

 Preferably, the pharmaceutical composition of the present invention comprises a licorice extract comprising 4 to 64 parts by weight of glycyrrhizic acid (or glycyrrhizic acid or glycyrrhetinic acid prepared) and 0.01 to 0.2 parts by weight of jujube ring gland. The jujube extract of the monoglyceride monophosphate is made of a raw material.

Preferably, the pharmaceutical composition of the present invention comprises a licorice extract containing 10 to 30 parts by weight of glycyrrhizic acid (or glycyrrhizic acid or glycyrrhetinic acid prepared) and a ring-shaped gland containing 0.024-0.12 parts by weight of jujube The jujube extract of the monoglyceride monophosphate is made of a raw material. Preferably, the pharmaceutical composition of the present invention, wherein the jujube extract used is the following second extract: first extracting jujube to obtain a first extract, and then purifying the first extract to obtain a second extract The concentration of the cyclic adenosine monophosphate (cAMP) of the second extract is higher than the concentration of the cyclic adenosine monophosphate of the extract of the first extract.

 According to another concept of the present invention, the present invention is a method for preparing a pharmaceutical composition for treating depression, comprising the steps of:

 (a) After crushing 2 to 32 parts by weight of licorice, first adding water to be immersed at room temperature, and then extracting by water extraction and alcohol precipitation, and then concentrating and drying the extracted supernatant to obtain licorice extract containing glycyrrhizic acid;

 (b) 2~42 parts by weight of jujube is broken and then extracted with water to obtain a first jujube extract, and the first jujube extract is separated and purified by column chromatography to obtain a second jujube extract. , wherein the concentration of the adenosine adenosine monophosphate of the second jujube extract is higher than the concentration of the adenosine adenosine monophosphate of the first jujube extract;

 (c) The licorice extract obtained in the steps (a) and (b) and the second jujube extract are mixed and pulverized to obtain the pharmaceutical composition of the present invention.

 Preferably, the pharmaceutical composition of the present invention can be processed into a dosage form comprising a lozenge, a capsule, a powder, a tablet, a powder, a solution, a tincture Any one of a suspension, an emulsion, a granule, a pill, a pill, and a pharmaceutically acceptable oral pharmaceutical dosage form.

 Preferably, the pharmaceutical compositions of the present invention comprise a pharmaceutically acceptable carrier or additive.

 Preferably, the pharmaceutical composition of the present invention further comprises a health food and a nutrient. The above pharmaceutical composition is a core component for achieving the object of the present invention. After the disclosure of the present invention, those skilled in the art can routinely add or subtract the above pharmaceutical composition according to the theory of traditional Chinese medicine or related modern pharmacological theory. Cut. Such conventional addition and subtraction is a general technical activity of those skilled in the art, and as long as it is a general technical addition or subtraction performed on the formulation base of the pharmaceutical composition of the present invention, it is within the scope of the present invention.

A better understanding of the present invention can be obtained by reference to the drawings and detailed description. BRIEF abstract

 BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a schematic view showing the flow of a method for preparing a medicament of Example 1 of the present invention.

 Fig. 2 is a flow chart showing the process of preparing the medicament of the embodiment 2 of the present invention. Preferred embodiment of the invention

 The invention will be further illustrated by the following figures and examples. The present invention is primarily directed to the preparation of the medicaments of the present invention in combination with the features of the present invention by methods well known to those skilled in the art. The following examples are merely illustrative of the invention and are not intended to limit the invention.

 In order to accomplish the object of the present invention, the present invention particularly proposes the following technical solutions.

 Option One:

 The pharmaceutical composition for treating depression of the present invention is prepared by using licorice and jujube as raw materials. Fang Zhong 2:

 The pharmaceutical composition for treating depression of the present invention is prepared by using 2 to 32 parts by weight of licorice and 2 to 42 parts by weight of jujube as raw materials.

 third solution:

 The pharmaceutical composition for treating depression is prepared by using 5 to 15 parts by weight of licorice and 4 to 20 parts by weight of jujube as a raw material.

 Option 4:

 The pharmaceutical composition for treating depression of the present invention is prepared by using a licorice extract and a jujube extract as raw materials.

 Option 5:

 The invention comprises a licorice extract containing 4 to 64 parts by weight of glycyrrhizic acid (or glycyrrhizic acid or glycyrrhetinic acid prepared) and a jujube extract containing 0.01-0.2 parts by weight of jujube cyclic adenosine monophosphate. A pharmaceutical composition for treating depression is invented.

 Option six:

To include licorice extract containing 10-30 parts by weight of glycyrrhizic acid (or glycyrrhizic acid or glycine which has been prepared) A jujube extract containing 0.024-0.12 parts by weight of jujube cyclic adenosine monophosphate is used as a raw material to prepare a pharmaceutical composition for treating depression.

 Option seven:

 The jujube extract according to the fourth aspect of the present invention is the following second extract: first extracting jujube to obtain a first extract, and then purifying the first extract to obtain a second extract; wherein the second extract The concentration of the adenosine adenosine monophosphate of the extract is higher than the concentration of the adenosine adenosine monophosphate of the first extract.

 Option eight:

 The pharmaceutical composition of the invention for treating depression is prepared by a preparation method comprising the following steps:

 (a) after crushing 2 to 32 parts by weight of licorice, first adding water at room temperature, then extracting by water extraction and alcohol precipitation, and then concentrating and drying the extracted supernatant to obtain licorice extract containing glycyrrhizic acid;

 (b) 2~42 parts by weight of the jujube is broken and then extracted with water to obtain a first extract, and the first extract is separated and purified by column chromatography to obtain a second extract, wherein the second extract is obtained. The concentration of the adenosine monophosphate of the jujube is higher than the concentration of the adenosine monophosphate of the jujube extract;

 (c) The licorice extract obtained in the steps (a) and (b) and the second extract of jujube are mixed and pulverized to obtain the pharmaceutical composition of the present invention.

 Option nine:

 The pharmaceutical composition of the present invention can be processed into a dosage form comprising a tablet selected from the group consisting of a tablet, a capsule, a powder, a tablet, a powder, a solution, a microtane, a suspension. Any one of an emulsion, a granule, a pill, a pill, and a pharmaceutically acceptable oral pharmaceutical dosage form.

 Option 10:

 The pharmaceutical compositions of the present invention comprise a pharmaceutically acceptable carrier or additive.

 Option 11:

 The pharmaceutical compositions of the present invention also include those useful in the manufacture of health foods and nutraceuticals.

 In order to accomplish the object of the present invention, a method of producing the following drugs is specifically proposed.

 method one:

The raw materials including licorice, jujube and the like are processed into the pharmaceutical composition for treating depression in the present invention. Things.

 Method Two:

 Raw materials such as 2 to 32 parts by weight of licorice and 2 to 42 parts by weight of jujube are processed to prepare a pharmaceutical composition for treating depression in the present invention.

 Method three:

 Raw materials such as 5 to 15 parts by weight of licorice and 4 to 20 parts by weight of jujube are processed to prepare a pharmaceutical composition for treating depression in the present invention.

 Method four:

 Raw materials such as licorice extract and jujube extract are processed to prepare a pharmaceutical composition for treating depression in the present invention.

 Method five:

 The licorice extract containing 4 to 64 parts by weight of glycyrrhizic acid (or prepared glycyrrhizic acid or glycyrrhetinic acid) and the jujube extract containing 0.01 to 0.2 parts by weight of jujube cyclic adenosine monophosphate may be processed. The invention relates to a pharmaceutical composition for treating depression.

 Method six:

 The licorice extract containing 10 to 30 parts by weight of glycyrrhizic acid (or prepared glycyrrhizic acid or glycyrrhetinic acid) and the jujube extract containing 0.024-0.12 parts by weight of jujube cyclic adenosine monophosphate are processed. The invention relates to a pharmaceutical composition for treating depression.

 Method seven:

 The jujube extract according to the fourth method is the following second extract: first extracting jujube to obtain a first extract, and then purifying the first extract to obtain a second extract; wherein the second extract The concentration of adenosine monophosphate in the jujube is higher than the concentration of the adenosine adenosine monophosphate in the first extract.

 Method eight:

 The pharmaceutical composition of the invention for treating depression is prepared by a preparation method comprising the following steps:

(a) after crushing 2 to 32 parts by weight of licorice, first adding water to be immersed at room temperature, extracting by water extraction and alcohol precipitation, and then concentrating and drying the extracted supernatant to obtain licorice extract containing glycyrrhizic acid; (b) 2~42 parts by weight of the jujube is broken and then extracted with water to obtain a first extract, and the first extract is separated and purified by column chromatography to obtain a second extract, wherein the second extract is obtained. The concentration of the adenosine monophosphate of the jujube is higher than the concentration of the adenosine monophosphate of the first extract;

 (c) The licorice extract obtained in the steps (a) and (b) and the second extract of jujube are mixed and pulverized to obtain the pharmaceutical composition of the present invention.

 Method nine:

 The pharmaceutical composition of the present invention is processed into a dosage form comprising a tablet selected from the group consisting of a tablet, a capsule, a powder, a tablet, a powder, a solution, a microtane, a suspension. , an emulsion, a granule, a pill, a pill, and any one of a pharmaceutically acceptable pharmaceutical dosage form.

 Method ten:

 The pharmaceutical compositions of the present invention are processed to include a pharmaceutically acceptable carrier or additive.

 Method 11:

 The pharmaceutical composition of the present invention is processed into a health food and a nutrient.

 Example 1

 Please refer to FIG. 1, which is a schematic flow chart of a method for preparing the pharmaceutical composition of Example 1 of the present invention. In Fig. 1, 4 kg of licorice is crushed, infiltrated with water for 12 hours, then extracted by warming, alcohol precipitation, and dried to obtain 0.8 kg of licorice extract containing 10% glycyrrhizic acid; 2 kg of jujube is broken, and water is added at room temperature. Then, it is extracted by water extraction and alcohol precipitation method, and the jujube extract is obtained. Then, the macroporous resin OU-2 and ME-2 are successively adsorbed and separated by two columns, and dried to obtain 6 g of jujube containing 1% jujube cAMP. Extract; The extract obtained in the above step is mixed and pulverized uniformly to obtain the pharmaceutical composition of the present invention.

 Example 2

 Please refer to FIG. 2, which is a schematic flow chart of a method for preparing the pharmaceutical composition of Example 2 of the present invention. In Fig. 2, the prepared 4 g of glycyrrhetinic acid and 1 g of jujube extract containing 10 mg of jujube cAMP were directly mixed and pulverized to obtain the pharmaceutical composition of the present invention.

 Experimental Example 1 Example 1 Effect on Mouse Suspension Experiment

1.1 Experimental animals ICR mice, male, weighing 22.0±2 g, secondary, provided by the Department of Laboratory Animal Science, Capital Medical University, Beijing.

 1.2 Experimental drugs

 Example 1: Provided by Beijing O'Neill Bioengineering Technology Co., Ltd.

 Paroxetine (Selite): Sino-US Tianjin Shike Pharmaceutical Co., Ltd. products.

 1.3 Real Instrument:

 Stopwatch.

 1.4 Dose design

 Example 1 The large dose was 20 mg/kg/d, the medium dose was 10 mg/kg/d, and the small dose was 5 mg/kg/d.

 1.5 Real-test methods and results

 1.5.1 Group administration

 Mice were randomized into groups of 10: 1 Example 1 large dose group (20 mg/kg, PO, 7d); 2 Example 1 dose group (10 mg/kg, PO, 7d) 3 Example 1 Low-dose group (5 mg/kg, PO, 7d); 4 paroxetine group (3 mg/kg, PO, 7d); 5 saline group (PO). A tail suspension experiment was performed 1 hour after the last administration.

 1.5.2 Real ^ r method

 The tail of the mouse (1 cm from the tip of the tail) was adhered to the 5 cm wooden strip with a tape on the head for 6 minutes, and the immobility time of the mouse within 5 minutes after the recording was recorded.

 1.5.3 Statistical processing

 The experimental data were expressed by ±SI>, and the experimental results were analyzed by SPSS 11.5 statistical software for analysis of variance.

 1.5.4 Real-risk results

 See Table 1 for the experimental results.

 Table 1. Effect of Example 1 on immobility time in mice

Number of animals in the group (only) No time (seconds) Saline group (model group) 10 122.18±45.78 Paroxetine group 10 67.59±32.09** Example 1 high dose group 10 54.67+26.38** Example 1 medium dose group 10 61.60±49.84** Example 1 low dose group 10 103.26+49.91 Note: Compared with the model group * P<0.05 * *P<0.01

 in conclusion:

 According to the above experiment, it can be seen that the large and medium dose groups and the paroxetine group of the present invention can reduce the immobility time of the mice after the tail suspension, and the large and middle dose groups and the saline group (model group) There is a significant difference in the ratio, so that it can be inferred that Example 1 of the present invention has an anti-experimental depression function.

 Experimental Example 2 Example 1 Effect of reserpine induced hypothermia in mice

 2.1 Experimental animals

 ICR mice, male, weighing 22.0±2 g, secondary, provided by the Department of Laboratory Animal Science, Capital Medical University, Beijing.

 2.2 Experimental drugs

 Example 1: Provided by Beijing O'Neill Bioengineering Technology Co., Ltd.

 Paroxetine (Selite): Sino-US Tianjin Shike Pharmaceutical Co., Ltd. products.

 2.3 Experimenter

 GM222 type electronic thermometer, stopwatch.

 2.4 Dose design

Example 1 The large dose is 20 mg/kg/d, the medium dose is 10 mg/kg/d, and the small dose is 5

 2.5 Experimental methods and results

 2.5.1 Group administration

Mice were randomized into groups of 10: 1 Example 1 high dose group (20 mg/kg, PO, 7d); 2 Example 1 dose group (10 mg / kg, PO, 7d); 3 Example 1 low dose group (5 mg / kg, PO, 7d); 4 paroxetine group ( 3 mg/kg, PO, 7d); 5 saline group (PO). 2.5.2 Experimental methods

 The anus temperature of the mice was measured 1 hour after the administration on the 8th day, and then the reserpine 2 mg/kg was intraperitoneally injected, and the anal temperature of the mice was measured 4 hours after the injection of reserpine. The depth and time of insertion of the thermometer into the anus of the mouse were consistent at each temperature measurement.

 2.5.3 Statistical processing

 The experimental data were expressed and the experimental results were analyzed by SPSS 11.5 statistical software. 2.5.4 Experimental results

 See Table 2 for the experimental results.

 Group Another 'J animal number (only) mouse body temperature drop value ( °C ) saline group (model group) 10 3.65 ± 0.77

 Paroxetine group 10 2.38+0.69**

 Example 1 High dose group 10 1.85+1.01**

 Example 1 Medium dose group 10 2.05+1.03**

 Example 1 Low dose group 10 3.30+0.69

 Note: Compared with the model group * p<0.05 * *P<0.01

 in conclusion:

 According to the above experiment, it can be seen that the large, medium and small dose groups and the paroxetine group of the present invention can reduce the decrease of body temperature induced by reserpine in the high dose group and the middle dose group and the saline group.

There is a significant difference (model group), so that it can be inferred that the embodiment 1 of the present invention has anti-experimental depression function ₍ modification, equivalent change and modification, all still fall within the scope of the technical scheme of the present invention. Industrial applicability

 The scope of application of the oral medicament of the present invention for treating depression:

 1. The oral drug for treating depression according to the present invention may comprise a pharmaceutically acceptable Additive P agent;

 2. The oral medicament for treating depression according to the present invention can be processed into various conventional dosage forms such as powders, capsules, tablets, and the like;

 3. The oral medicament for treating depression according to the present invention can be used for the treatment of health foods and nutrients for depression.

Claims

Claim A pharmaceutical composition for treating depression, comprising a licorice and a jujube as a raw material. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition comprises 2 to 32 parts by weight of the licorice and 2 to 42 parts by weight of the jujube as a raw material. . The pharmaceutical composition according to claim 2, wherein the pharmaceutical composition further comprises 5 to 15 parts by weight of the licorice and 4 to 20 parts by weight of the jujube as a raw material. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition contains a carrier selected from a pharmaceutically acceptable one, an additive, or a combination thereof. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is formulated into a dosage form comprising a tablet, a capsule, a powder, a tablet, a powder, and a dosage form. Any one of a solution, a microinjector, a suspension, an emulsion, a granule, a pill, a pill, and a pharmaceutically acceptable oral pharmaceutical dosage form. 6. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is formulated into a health food or a nutrient. A pharmaceutical composition for treating depression, comprising a jujube extract and a glycyrrhizic acid as a raw material, wherein the glycyrrhizic acid comprises a glycyrrhizic acid extract, a glycyrrhizic acid, a licorice Any of a hypoacid and a combination thereof. The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition comprises the jujube extract containing 0.01-0.2 parts by weight of jujube cyclic adenosine monophosphate and the solution containing 4-64 parts by weight of glycyrrhizic acid. The licorice extract is described. The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition comprises the jujube extract containing 0.01-0.2 parts by weight of jujube cyclic adenosine monophosphate and 4 to 64 parts by weight selected from the group consisting of Any one of glycyrrhizic acid, the glycyrrhetic acid, or a combination thereof. . The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition comprises the jujube extract containing 0.024 to 0.12 parts by weight of jujube cyclamate and 10 to 30 parts by weight of glycyrrhizic acid. The licorice extract. The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition further comprises the jujube extract containing 0.024 to 0.12 part by weight of jujube cyclic adenosine monophosphate and 10 to 30 parts by weight of the selected Any one of glycyrrhizic acid, the glycyrrhetic acid, or a combination thereof. The pharmaceutical composition according to claim 7, wherein the raw material containing jujube cyclic adenosine monophosphate is a second extract: first extracting a large jujube to obtain a first extract, and then purifying the The first extract obtains the second extract, wherein the concentration of the jujube cyclic adenosine monophosphate of the second extract is higher than the concentration of the jujube cyclic adenosine monophosphate of the first extract. 13. The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition comprises a carrier selected from the group consisting of a pharmaceutically acceptable carrier, an additive, or a combination thereof. The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition is formulated into a dosage form comprising a tablet selected from the group consisting of a tablet, a capsule, a powder, a tablet, a powder, and a Any one of a solution, a microinjector, a suspension, an emulsion, a granule, a pill, a pill, and a pharmaceutically acceptable oral pharmaceutical dosage form. The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition is formulated into a health food or a nutrient. A method for preparing a pharmaceutical composition for treating depression, comprising the steps of: (a) extracting 4 to 64 parts by weight of licorice to obtain a first licorice extract; (b) extracting 2 to 42 parts by weight of a large jujube, and obtaining a first jujube extract; (c) purifying the extract of the jujube and jujube extract, and obtaining an extract of jujube and jujube; (d) mixing the first licorice extract and the second jujube extract to obtain the pharmaceutical composition, The concentration of the cyclic adenosine monophosphate of the jujube extract of the second jujube extract is higher than the concentration of the cyclic adenosine monophosphate of the jujube extract of the first jujube extract. The preparation method according to claim 16, wherein the step (a) further comprises: (al) Purifying the first licorice extract to obtain a second licorice extract, wherein the second licorice extract has a glycyrrhizic acid concentration higher than a glycyrrhizic acid concentration of the first licorice extract. The preparation method according to claim 16, wherein the step (c) is: adsorbing and separating the jujube cyclic adenosine monophosphate in the first jujube extract by using a macroporous resin upper column containing a waking group. The preparation method according to claim 18, wherein the step (c) is carried out by adsorbing and separating the jujube cyclic adenosine monophosphate in the first jujube extract by using a matrix-containing macroporous resin OU-2. The preparation method according to claim 18, wherein the step (c) further separates the jujube cyclic adenosine monophosphate in the first jujube extract by a column of a resin ME-2.